Literature DB >> 8662817

Conformation of human leukocyte antigen class II molecules. Evidence for superdimers and empty molecules on human antigen presenting cells.

C Roucard1, F Garban, N A Mooney, D J Charron, M L Ericson.   

Abstract

Subpopulations of human leukocyte antigen (HLA) class II molecules were studied in antigen presenting cells. We present evidence for double dimers or "superdimers" of HLA class II molecules that were stable in an SDS solution at room temperature but dissociated when heated to 50 degrees C into 60-kDa alphabeta heterodimers. Development of an immunofluorescence assay allowed us to quantify the expression of HLA antigens as reflected by the number of bound isotype-specific monoclonal antibodies per cell. The total expression of class II (DR, DQ, and DP) augmented 6-fold after a 36-h interferon-gamma (IFNgamma) treatment of freshly isolated monocytes. Next, we used a recombinant and fluorescein-conjugated form of the class II-associated invariant chain as a quantitative probe for empty peptide-binding sites. The fraction of empty class II molecules was 0.73-2.9% in resting monocytes but was reduced to 0. 12-0.5% of the total after IFNgamma treatment. The fraction of empty sites in B lymphocytes was 0.09-0.36%. The mean number of empty sites per cell were: 6.3 x 10(3) (monocytes), 7.2 x 10(3) (IFNgamma-activated monocytes), 5.2 x 10(2) (B lymphocytes), and 3.6 x 10(3) (Raji B cells). A minor population (4.3-7.4% of total cells), which expressed a much higher number of empty sites, was consistently present in all cell types studied.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662817     DOI: 10.1074/jbc.271.24.13993

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  The immune function of MHC class II molecules mutated in the putative superdimer interface.

Authors:  John D Hayball; Richard A Lake
Journal:  Mol Cell Biochem       Date:  2005-05       Impact factor: 3.396

2.  Zinc induces dimerization of the class II major histocompatibility complex molecule that leads to cooperative binding to a superantigen.

Authors:  Hongmin Li; Yiwei Zhao; Yi Guo; Zhong Li; Leslie Eisele; Walid Mourad
Journal:  J Biol Chem       Date:  2006-12-13       Impact factor: 5.157

3.  The tetraspanin CD9 mediates lateral association of MHC class II molecules on the dendritic cell surface.

Authors:  Julia J Unternaehrer; Amy Chow; Marc Pypaert; Kayo Inaba; Ira Mellman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-26       Impact factor: 11.205

4.  Tetraspanin-5-mediated MHC class I clustering is required for optimal CD8 T cell activation.

Authors:  Jeff D Colbert; Freidrich M Cruz; Christina E Baer; Kenneth L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2022-10-10       Impact factor: 12.779

5.  A highly tilted binding mode by a self-reactive T cell receptor results in altered engagement of peptide and MHC.

Authors:  Dhruv K Sethi; David A Schubert; Anne-Kathrin Anders; Annie Heroux; Daniel A Bonsor; Chantz P Thomas; Eric J Sundberg; Jason Pyrdol; Kai W Wucherpfennig
Journal:  J Exp Med       Date:  2011-01-03       Impact factor: 14.307

6.  Self-reactive human CD4 T cell clones form unusual immunological synapses.

Authors:  David A Schubert; Susana Gordo; Joseph J Sabatino; Santosh Vardhana; Etienne Gagnon; Dhruv K Sethi; Nilufer P Seth; Kaushik Choudhuri; Helena Reijonen; Gerald T Nepom; Brian D Evavold; Michael L Dustin; Kai W Wucherpfennig
Journal:  J Exp Med       Date:  2012-02-06       Impact factor: 14.307

7.  Detection of dimers of dimers of human leukocyte antigen (HLA)-DR on the surface of living cells by single-particle fluorescence imaging.

Authors:  R J Cherry; K M Wilson; K Triantafilou; P O'Toole; I E Morrison; P R Smith; N Fernández
Journal:  J Cell Biol       Date:  1998-01-12       Impact factor: 10.539

8.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.